---
name: credibility-translation
description: >
  Translate clinical, academic, and trial-development credentials into the operator,
  investor, or board vocabulary the target audience parses. Reference when rewriting bullets
  for a non-clinical audience, preparing to explain trial work to a VC, or auditing whether
  the audience can recognize the value of the user's experience. Untranslated credibility
  is invisible to the wrong audience — and the wrong audience is most audiences outside
  clinical settings.
metadata:
  author: nirav
  version: "1.0"
compatibility: Designed for Claude Code
allowed-tools: Read
---

# Credibility Translation — Making Earned Expertise Legible

A clinical scientist who ran a 600-patient Phase 2 with a co-primary endpoint and a regulatory interaction has earned a specific kind of credibility: high-stakes execution under uncertainty, with regulator-as-customer judgment, and ownership of decisions that move billion-dollar programs. That credibility is invisible to a VC partner who reads "Director, Clinical Scientist — managed clinical trial."

Credibility translation is not embellishment. It is the deliberate act of converting domain-specific vocabulary into the vocabulary the target audience uses to evaluate seniority, judgment, and ownership.

## Key Concepts

### The Translation Matrix

Every credible piece of clinical work has three properties the target audience cares about:

1. **Stakes** — what was the consequence if you got it wrong? (financial, regulatory, scientific)
2. **Ownership** — what specifically did *you* decide, vs the team, vs the PI?
3. **Outcome** — what happened? (with metrics where available)

The translation rewrites each clinical bullet through this matrix in the audience's vocabulary.

### Audience-by-Audience Translation Examples

Same underlying work — "Led the protocol amendment for the Phase 2 expansion cohort" — translated:

| Audience | Translation | Why this lands |
|---|---|---|
| Clinical peer | "Led the protocol amendment to add the 200-patient expansion cohort with a biomarker-stratified design" | Shared vocabulary; details matter |
| Recruiter | "Owned a Phase 2 protocol amendment, expanding the trial by 200 patients with a biomarker enrichment strategy" | Outcome and scope visible; lightly de-jargoned |
| VC partner | "Owned the Phase 2 expansion decision, including the biomarker-stratified design choice that increased the program's PoS by ~15% and informed our $40M Series B raise" | Stakes (PoS, capital) explicit; decision ownership clear |
| Board candidate | "Owned the Phase 2 expansion that the board green-lit at $20M incremental cost; the biomarker design choice changed our regulatory pathway from accelerated approval to full approval, with consequent commercial implications" | Governance frame; capital and regulatory consequence |

The underlying truth does not change. What changes is which dimensions are surfaced and what vocabulary names them.

### The Vocabulary Substitution Table

Common clinical-to-operator translations:

| Clinical Vocabulary | Operator/Investor Vocabulary |
|---|---|
| Ran the trial | Owned the [scope/$] execution risk |
| Endpoint selection | The diligence call that drives PoS and label |
| Protocol amendment | The mid-program decision that re-prices the asset |
| FDA interaction | Regulator-as-customer relationship management |
| Co-investigator on a paper | Co-author on the data package that supports the program's claim |
| Adverse event review | Risk surveillance that informs go/no-go decisions |
| IRB submission | Stakeholder negotiation under regulatory framework |
| ICH-GCP compliance | Audit-ready operational discipline |
| DSMB interaction | Independent governance interface for the program |

### Failure Modes to Avoid

| Failure Mode | What It Looks Like | What It Signals |
|---|---|---|
| Over-translation | "Owned the strategic transformation of our therapeutic asset's regulatory positioning" | Reads as MBA-jargon overlay; pattern-matched as low substance |
| Under-translation | "Worked on the trial" | Reads as low ownership; pattern-matched as junior |
| Vocabulary mismatch with role | Using VC-speak in a CMO interview | Reads as not actually wanting the role you're applying for |
| Inflation without substance | Claiming "owned" what you actually contributed to | Detectable in technical follow-up; ends candidacy |

### The Calibration Test

A good translation passes two tests:

1. **The clinical peer test** — would a peer who was on the trial nod at the description, or call it inflated?
2. **The target audience test** — would the target reader (VC partner, recruiter, board chair) read it as substantive senior work?

A translation that passes both is correct. A translation that passes only the audience test is inflation.

## Self-Coaching Track

**For your situation (MD → biotech VC/operator):**

1. **Inventory your top 5 pieces of clinical work** from the last 5 years. For each, write three lines: (a) what it was in clinical vocabulary, (b) the stakes, (c) what *you* specifically decided.

2. **For each, draft the VC-partner translation.** Use the matrix above. Make ownership and stakes explicit. Quantify where possible (sample size, $ value, PoS change, timeline impact).

3. **Run the calibration test.** For each translation, ask: would a clinical peer who knows the work nod at this, or push back as inflation? If push-back, dial down. Then ask: would a VC partner read this as substantive operator work? If no, dial up the stakes/ownership clarity.

4. **Build the substitution table for your specific work.** General matrix above is a starting point; your work has specifics. Build a personal table mapping your clinical vocabulary to your operator-target vocabulary. Reuse across resume, LinkedIn, cover letters, interview answers.

5. **Stress-test in mock conversation.** Have a non-clinical friend (ideally with some business context) read your translated bullets. Ask: "What does this person do, and why would I want them on my team?" If they can't answer, the translation is broken.

6. **Audit for over-translation.** Re-read every translated bullet. If it reads more like an MBA case-study summary than the actual work, dial back. The signal is specificity + clear ownership + named stakes — not jargon density.

## Teach / Mentor-Others Track

**When coaching a junior or peer through credibility translation:**

1. **Start with the matrix (stakes, ownership, outcome).** This is the durable framework. Once they have it, they can translate any future work without coaching.

2. **Show one good translation and one bad translation.** Side-by-side comparison teaches faster than abstract advice. Use the table above or one from their actual work.

3. **Force ownership clarity.** Mentees often write "we" or "the team" — these are honest but they erase the user from the credibility. Coach them to write what *they* specifically did, even when the work was collaborative. ("I led the design; the team executed.")

4. **Calibrate against inflation.** The most common failure for mentees is inflation. Ask repeatedly: "Would a peer who was there nod at this?" If they hesitate, the bullet is inflated.

5. **Audience-mismatch is a common failure.** A mentee preparing for both CMO interviews and VC interviews often writes one set of bullets in one vocabulary. Coach them to maintain two parallel translations of the same work — same truth, different vocabulary.

6. **Translation is a gateway skill to interview answers.** Once a mentee can translate bullets, they can also translate live interview stories. Use the same matrix as the prep tool.

## When This Applies

- Rewriting a resume or LinkedIn for a non-clinical audience
- Drafting a cover letter for a VC, board, or operator role
- Preparing interview answers
- Auditing why current outreach is not converting (often the bullets read as junior-clinical to non-clinical readers)
- Making the public portfolio readable to a target audience

## Cross-Domain Connections

- **personal-positioning/narrative-architecture** — Translation serves the named through-line
- **personal-positioning/audience-tuning** — The translation matrix is the substrate; audience tuning applies it per audience
- **personal-positioning/resume-craft, cover-letter-craft, linkedin-optimization** — Surfaces that consume translated bullets
- **interview-mastery/behavioral-frameworks** — Live translation of stories in interviews
- **biotech-venture/asclepius** — Source of the underlying clinical content
- **binding-vow/audience-classifier** — Audience taxonomy that drives translation choices